Price T Rowe Associates Inc Outlook Therapeutics, Inc. Transaction History

Price T Rowe Associates Inc

  • $836 Billion
  • Q2 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023
BUY
$0.2 - $1.78 $831 - $7,399
4,157 Added 14.23%
33,369 $8,000
Q1 2023

May 15, 2023
BUY
$1.0 - $1.35 $9,973 - $13,463
9,973 Added 51.84%
29,212 $32,000
Q4 2022

Feb 14, 2023
BUY
$0.87 - $1.33 $2,297 - $3,512
2,641 Added 15.91%
19,239 $21,000
Q3 2022

Nov 14, 2022
BUY
$1.02 - $1.26 $5,516 - $6,814
5,408 Added 48.33%
16,598 $21,000
Q2 2022

Aug 15, 2022
BUY
$0.91 - $2.01 $10,182 - $22,491
11,190 New
11,190 $11,000

Others Institutions Holding OTLK

# of Institutions
3
Shares Held
31.5K
Call Options Held
0
Put Options Held
0
View Full List

About Outlook Therapeutics, Inc.

OTLK Quotes by TradingView
  • Ticker OTLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 226,144,992
  • Market Cap $1.18B
  • Description
  • Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...
More about OTLK
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email